Alzheimer’s Drugs Study: 20,000 Patients Reveal Lack of Clinical Benefit and Increased Risks
Recent research involving 20,000 participants has raised significant questions about the effectiveness of newly approved Alzheimer’s drugs, prompting a broader reassessment of treatment strategies for the neurodegenerative condition. The findings, which emerged from a large-scale analysis published in early 2024, indicate that despite regulatory approvals in several countries, the clinical benefits of anti-amyloid therapies remain … Read more